https://www.selleckchem.com/pr....oducts/pci-34051.htm
Increasing the drug tumor-specific accumulation and controlling their release is considered one of the most effective ways to increase the efficacy of drugs. Here, we developed a vesicle system that can target hepatoma and release drugs rapidly within tumor cells. This non-ionic surfactant vesicle is biodegradable. Galactosylated stearate has been used to glycosylate the vesicles to achieve liver targeting; replacement of a portion (CholCHEMS = 11) of cholesterol by cholesteryl hemisuccinate (CHEMS) allows for a rapid release of drugs

https://www.selleckchem.com/pr....oducts/Epinephrine-b
Recent advancements in molecular characterisation have identified four principal molecular groups of medulloblastoma WNT, SHH, group 3 and group 4. Each has its characteristic clinical features, signature genetic alterations and distinct DNA methylome profiles. Thus far, CTNNB1 mutations have been considered pathognomonic of WNT-activated medulloblastoma. Furthermore, it has been shown that CTNNB1 mutations dominantly drive the WNT-activated phenotype in medulloblastoma, even in the presence of alterations in